Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Larry Saltzman
Sacramento doctor: If not for NIH funding, I wouldn’t have survived my leukemia diagnosis | Opinion Original
Following a terminal leukemia/lymphoma diagnosis in 2010, my physicians estimated that I would live no more than five to eight years. Today, I am seven years past that expiration date and going strong. I can thank the investments in research made by the National Institutes of Health and other non-profit organizations — notably, the Leukemia & Lymphoma Society — which have allowed me to survive my leukemia.
How Are Patients Selected for CAR T-Cell Therapy?
View next Published on April 22, 2022 Experts Explain the CAR T-Cell Therapy Decision Process With CAR T-cell therapy approved for some blood cancers and in trial for others, when do doctors recommend CAR T for patients?
Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies
Main text It has been reported that ∼15%–25% of patients with hematologic malignancies fail to make anti-spike (anti-S) antibodies in response to full dosing of SARS-CoV-2 mRNA vaccines (; ). Patients with B cell malignancies are at the highest risk of not making anti-S antibodies. Although the complete immune response in B and T cells is not fully understood, these findings suggest that seronegative patients may be vulnerable to breakthrough infections.
Is the COVID Vaccine Effective in People With Blood Cancer?
View next Published on August 11, 2021 Study Shows Varying Vaccine Response in Blood Cancer Patients In this segment, Dr. Larry Saltzman, MD, Executive Research Director of the Leukemia & Lymphoma Society, explains that some blood cancer patients may have little to no immunity to COVID-19 even after being fully vaccinated. Dr. Saltzman also shares that immunity levels can vary depending on your blood cancer type and the treatments you are receiving. Keep watching to learn more.
Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies
Main text The mRNA vaccines BNT162b2 and mRNA-1273 have robust safety and efficacy against COVID-19 among immunocompetent individuals (). However, many hematologic patients fail to produce anti-spike antibodies after full vaccination (), particularly in patients with B cell malignancies, including chronic lymphocytic leukemia (). The effect is correlated with the disease itself and/or the treatments that are immunosuppressive.
Registry aims to improve understanding of how COVID-19 affects patients with blood cancer
February 27, 2021 2 min read Save Source/Disclosures Published by: Disclosures: Saltzman reports employment with Leukemia & Lymphoma Society. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CLL and CAR-T Cell Therapy: Is It Right for Me?
Andrew Schorr: We CLL patients have been learning, do we have different, are we mutated or unmutated, do we have the 17P deletion that could be more aggressive? Dave, do you know anything about the characteristics of your CLL that made your CLL more aggressive? Dave Garcia: I believe I am a 17. Andrew Schorr: 17P. Okay. And Larry, how about you? Dr. Saltzman: Yeah, so I'm a 13Q deletion, an 11Q deletion, and I am IVGH unmutated. Andrew Schorr: Okay. All right.
CLL Survivors Share Their CAR-T Cell Experience
Andrew Schorr: Good morning. Good afternoon. Good evening. Wherever you are in the world. I'm Andrew Schorr near San Diego. Welcome to this CLL Answers Now program. Thank you so much. I've been living with chronic lymphocytic leukemia for 24 years. I had the FCR chemo and rituximab (Rituxan) treatment in a clinical trial many years ago, about 17 years ago, and then had a monoclonal antibody treatment with steroids about two years ago and I'm doing well. Some people never have treatment for CLL.
Combatting Cost: How Can Clinical Trial Participation Help Patients Access Treatment?
Why should chronic lymphocytic leukemia (CLL) patients consider a clinical trial? What is the difference in treatment opportunities at community versus academic medical centers? Experts Dr. Kathleen Toomey, Dr. Gwen L. Nichols and Larry Saltzman share ways patients can benefit from participating in a clinical trial. Watch as the panel discusses cost of care, and testing and monitoring of patients in trials. Sponsored by Janssen Oncology and Pharmacyclics LLC.
Why You Should Speak Up About Struggling to Pay for Treatment
Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you. Andrew Schorr: Right, so I wanna about that—right. You mentioned as a physician people don’t always level with you, maybe they’re even embarrassed to tell you.
Stress, Treatment and Affordability: Resources to Help Patients Cope
Many people experience financial hardship after being diagnosed with chronic lymphocytic leukemia (CLL). Where can families dealing with cancer find financial assistance? Watch as Hildy Dillon shares how the Cancer Support Community can help patients cope with the expense of CLL care. This program is sponsored through a grant from Janssen Oncology and Pharmacyclics LLC. These organizations have no editorial control. It is produced solely by Patient Power.
Access to Treatment and Sophisticated Testing: What Barriers Do Patients Face?
Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.
What Is the Goal of CLL Frontline Treatment?
At a recent town meeting in Atlanta, Patient Power host and advocate Jeff Folloder was joined by renowned chronic lymphocytic leukemia (CLL) expert Dr. Jonathon Cohen, from the Emory University School of Medicine, to discuss first- and second-line treatment options and explain the goals of frontline therapy. Watch now to find out more.
CLL Access to Care: How Patients Can Get Access to the Latest Treatments
Patient Power’s Andrew Schorr is joined by CLL experts to discuss access issues for patients. Dr. Gwen L. Nichols and Dr. Larry Saltzman of The Leukemia & Lymphoma Society (LLS), Hildy Dillon from Cancer Support Community, and Dr. Kathleen Toomy of Regional Cancer Care Associates each share insights on to how patients can navigate access issues.
News From the American Society of Hematology (ASH) 2018 Annual Meeting
Patient Power was on-site at the 2018 American Society of Hematology (ASH) meeting in San Diego, Calif, to bring you the latest blood cancer-related treatment and research news. Look for new and expanded programs added day by day.
ASH 2018 Daily Wrap: MPN News
Patient Power founders Andrew and Esther Schorr are joined by a panel of experts, including, Dr. Robyn M. Scherber, from the Mays Cancer Center at UT Health San Antonio MD Anderson, Dr. Naveen Pemmaraju, from The University of Texas MD Anderson Cancer Center, and Dr. Larry Saltzman, from The Leukemia & Lymphoma Society (LLS),as they discuss research developments announced at the 2018 American Society of Hematology (ASH) meeting in San Diego, CA.
Strategies for Managing Head and Neck Cancer Treatment Side Effects
Side effects from head and neck cancer treatment may include damage to the taste buds and salivary glands. What can patients do to recover impaired sensation? How can moisture be restored to xerostomia, also known as dry mouth? Dr. Brad Mons, a head and neck surgeon from the Comprehensive Care and Research Center in Tulsa, Oklahoma, discusses medicines available and surgical reconstruction options to protect a person’s oral health and regain their ability to salivate, taste and swallow.
Larry's Update: Practically Perfect
In 1964, the film “Mary Poppins” was released. Although it did not win the Oscar for Best Picture (“My Fair Lady” won), Mary herself was, as they said—“practically perfect” in every way. And so it seems, at the moment, is my blood. For the past two years, I have been treated essentially on my own clinical trial where I have been taking a combination of two oral chemo-like drugs—not exactly chemo but “targeted” immunotherapy.
How Can Your Data Sharing Improve Cancer Treatment?
Patient data is invaluable to drive cancer research and treatment forward, and with a few clicks patients can become actively involved in improving cancer care for all.
Inspiration, Perspiration, Medication
I was on the phone with a friend during my last infusion when I mentioned the name of Mike Levine. I’d seen his photo the day before in a magazine while in flight back home. Medical personnel in the room with me looked up and said, “He’s treated here.” His name is obviously well-known at this San Diego area cancer center, and why not? On October 14th, Mike entered the grueling IRONMAN triathlon despite having stage IV pancreatic cancer.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Larry
Contact Larry, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack